Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
13,115 people get ARNA articles and Market Currents by email alert.
Get email alerts on ARNA »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Arena's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012 • 10 Comments
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call TranscriptTue, Nov 10, 2009
-
Arena Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
Arena Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Arena Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Arena Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptWed, May 7, 2008 • 1 Comment
-
Arena Pharmaceuticals Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
Arena Pharmaceuticals Q3 2007 Earnings Call TranscriptWed, Oct 17, 2007
-
PR Newswire (Fri, 8:00AM)
-
PR Newswire (Fri, 7:30AM)
-
PR Newswire (May 24, 2013)
-
PR Newswire (May 10, 2013)
-
at CNBC.com (May 2, 2013)
-
PR Newswire (May 2, 2013)
-
at CNBC.com (Apr 11, 2013)
-
PR Newswire (Apr 5, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 6, 2013)
-
at CNBC.com (Feb 5, 2013)
-
PR Newswire (Jan 2, 2013)
-
at CNBC.com (Dec 17, 2012)
ARNA vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas:... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, June 14, 10:49 AM ConsumerReports advises overweight individuals to just "skip" Arena Pharmaceuticals' (ARNA -2.2%) Belviq citing "slim results" and "risks galore." The nonprofit says its medical advisers note that users can expect to lose only 3-3.7% of their body weight over the course of a year and may gain it back. Risk factors cited in the report include "headache, dizziness, fatigue, nausea, dry mouth, and constipation." The report recommends the following alternative: "eat less and exercise." 22 Comments [Healthcare, On the Move]
- Tuesday, June 11, 6:49 PM Arena Pharmaceuticals's (ARNA) ticks higher in the post-session after its CEO told CNBC he sees its obesity drug Belviq as "transformative." (Video). Shares +2.3% AH. Comment! [Healthcare, On the Move]
- Friday, June 7, 8:47 AM Arena Pharmaceuticals (ARNA) rises 2.42% premarket after announcing that BELVIQ will be available in U.S. pharmacies beginning on June 11. The company earns $65M in milestone payments from partner Eisai (ESALF.PK) in connection with the launch. (PR) 3 Comments [Healthcare, On the Move]
- Tuesday, May 7, 12:45 PM Arena Pharmaceuticals (ARNA +8.2%) ramps higher today as the company moves closer than it's ever been to bringing its obesity drug Belviq to the U.S. market. A notice on the DEA's website says regulators have approved the scheduling of Belviq as a controlled substance. The notice will be published in the Federal Register tomorrow, and Belviq can be sold 30 days after. 3 Comments [Healthcare, On the Move]
-
Friday, May 3, 9:10 AM
Premarket gainers: PKT +32%. YRCW +27%. INVN +18%. YY +8%. DDD +5%.
Losers: VCRA -35%. ZAGG -24%. GUID -23%. CHE -16%. ARNA -13%. CETV -13%. HMY -9%. LNKD -9%. AGNC -6%. RBS -6%. 3 Comments [On the Move] -
Thursday, May 2, 6:10 PM
After-hours top gainers, as of 5:15 p.m.: PKT +23%. BCOR +12%. INVN +8%. FORM +7%. FLT +6%.
After-hours top losers: ZAGG -26%. VCRA -26%. GUID -20%. ARNA -15%. BRKR -11%. Comment! [On the Move] - Thursday, May 2, 6:06 PM More on Arena Pharmaceuticals (ARNA): Q1 misses EPS estimates badly, but adding to an afternoon beating by investors is the company's disclosure that it's withdrawn a regulatory application to sell its weight-loss Belviq therapy in the European Union after calculating it wouldn't get a positive decision. Shares -15.7% AH. Comment! [Earnings, Healthcare, On the Move, Global & FX]
- Thursday, May 2, 4:37 PM Arena Pharmaceuticals (ARNA): Q1 EPS loss of $0.09 misses by $0.20. Revenue of $2.4M (-9% Y/Y). (PR). Shares -11.7% AH. 4 Comments [Healthcare, Earnings, On the Move, Breaking News]
- Friday, April 5, 12:06 PM Arena Pharmaceuticals (ARNA -1.8%) loses steam with the rest of the overall market despite its announcement that it was initiating dosing in a Phase 1 clinical trial of APD334, a potential treatment of autoimmune diseases. The trial is set to evaluate safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64 volunteers. 1 Comment [Healthcare, On the Move]
- Monday, April 1, 11:51 AM Shares in Arena Pharmaceuticals (ARNA -2.2%) turn south this morning, shrugging off an earlier announcement of a $500K milestone payment from Eisai on the submission of a marketing authorization application for Belviq with regulatory authorities in Mexico. About 30% of adults in Mexico are obese and 70% are overweight or obese, which the company says is leading to a significant health and economic burden in the country. Comment! [Healthcare, On the Move, Global & FX]
-
Friday, March 22, 5:44 PM
After-hours top gainers, as of 5:15 p.m.: SFD +6%. REGI +6%. GTI +4%. FIVE +4%. KWK +4%.
After-hours top losers: IDIX -10%. TTS -6%. SVU -4%. MTG -3%. ARNA -2%. 3 Comments [On the Move] - Monday, March 4, 10:33 AM Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months after commercial marketing began. Bloomberg's Andrew Berens says the company will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75, which is 70% below the current price. The move could pose risks for Arena's (ARNA -4.4%) Belviq, which is a competitor to Qsymia. 6 Comments [Healthcare, On the Move]
- Monday, February 25, 2:45 PM Arena Pharmaceutical (ARNA +1.4%) trades in the green today after earlier disclosing the price for a 60-day supply of Belviq 10-mg tablets at $199.50. This compares with Vivus' (VVUS +1%) Qsymia, which retails for $160 per month at a medium dose and $220 per month for the higher dose. Analysts note the success of Belviq will largely depend on lower co-payments and broader insurance coverage, which could come in the next two years. 5 Comments [Healthcare, On the Move]
- Wednesday, February 6, 12:20 PM Shares of Arena Pharmaceutical (ARNA +1.8%) and Vivus (VVUS +3.3%) both gain today, after Leerink Swann resumes coverage on both with an Outperform rating. The firm gives VVUS a price target range of $19 - $20. 2 Comments [Healthcare, On the Move]
-
Tuesday, January 22, 12:45 PM
Midday top 10 gainers: PBIB +32%. DQ +18%. TECUA +18%. ONP +17%. USEG +17%. RDCM +17%. CIMT +14%. BOX +14%. MTRX +12%. PRCP +12%.
Midday top 10 Losers: CALI -12%. OIBR -12%. BVX -10%. DOM -9%. ARNA -8%. IIVI -8%. AMRI -8%. UPI -8%. IPXL -8%. EXFO -7%. Comment! [On the Move] - Tuesday, January 22, 9:43 AM Arena Pharmaceuticals (ARNA) slides 7.8% and adds to a 6.5% loss on Friday after the EU's CHMP health regulator didn't make a decision about approving the company's Belviq weight-loss treatment at meetings last week, meaning the firm will have to wait for at least another month for a ruling. It doesn't help that Arena received a 180-day list of questions about Belviq. "It's not pretty," says Adam Feuerstein. (Arena 8-K) 3 Comments [On the Move, Healthcare]
-
- View all 21 replies
-
-
phemale60: so, I'm the "other fool" LOL seen KNDI/OSH up so jumped on- a lesson I should've learned by now. Also KNDI is Chinese&very risky- too late!
-
- View all 4 replies
-
oneotherfool: No clue. I can only guess (for $ARNA) a last run down (bear raid or wtv u wanna call it) on a weak market day?
-
oneotherfool: Looks like alot of stops have been triggered and volume increased, scaring people out. We did see an upgrade yesterday.
-
Kellie Peterson
will $ARNA heat up or fizzle out going into launch of Belviq....I think up for now and then we'll see with sales data in a couple months - View all 0 replies
-
- View all 0 replies
-
Jacob Smith
$ARNA YMB poster thinks that shorts might actually cause a short squeeze to profit long on a sky rocketing price over the next few months - View all 0 replies
-
- View all 2 replies
-
ReaperLynx: I'll wait for another dip below $7.50......maybe $7.75 to add more. -
-
Day Trader001
Looks like $ARNA 's management strategy is still paying off , versus, VVUS "lack of strategy" rush to market! - View all 2 replies
-
-
Day Trader001: LOL....I believe ARNA is the Tortise here!! VVUS is now following ARNA's act.......
-
- View all 2 replies
-
-
dinoyc: I think they are both positioned to do well. Market is broad and it's only 2 players specially if they keep expanding around world.
-
- View all 0 replies
-
The Wall Street Transcript
Arena Pharmaceuticals' ($ARNA) Weight-Loss Drug Approved by FDA; 3% Weight Loss Recorded- http://su.pr/29wRUI - View all 2 replies
-
-
LATEST REPLIES
-
- View all 21 replies
-
-
phemale60: so, I'm the "other fool" LOL seen KNDI/OSH up so jumped on- a lesson I should've learned by now. Also KNDI is Chinese&very risky- too late!
-
- View all 4 replies
-
oneotherfool: No clue. I can only guess (for $ARNA) a last run down (bear raid or wtv u wanna call it) on a weak market day?
-
oneotherfool: Looks like alot of stops have been triggered and volume increased, scaring people out. We did see an upgrade yesterday.
-
- View all 2 replies
-
ReaperLynx: I'll wait for another dip below $7.50......maybe $7.75 to add more.
-
-
Day Trader001
Looks like $ARNA 's management strategy is still paying off , versus, VVUS "lack of strategy" rush to market! - View all 2 replies
-
-
Day Trader001: LOL....I believe ARNA is the Tortise here!! VVUS is now following ARNA's act.......
-
- View all 2 replies
-
-
dinoyc: I think they are both positioned to do well. Market is broad and it's only 2 players specially if they keep expanding around world.
-
Day Trader001
I believe the Withdraw for European Application of Belviq is an intelligent tactical move by $ARNA! Better than being denied like others. - View all 6 replies
-
-
Day Trader001: Hi Phe, good article, I don't know where ya got the other stuff are you talking about VVUS?
-
The Wall Street Transcript
Arena Pharmaceuticals' ($ARNA) Weight-Loss Drug Approved by FDA; 3% Weight Loss Recorded- http://su.pr/29wRUI - View all 2 replies
-
-
-
- View all 2 replies
-
-
oneotherfool: Agreed. I had a bid ready in high 6s if it dipped on the open...I canceled it. I won't buy more at this point. Back to the waiting game :)
-
Iamstockgeniusjustaskme
$ARNA isn't withdrawing the application similar to saying they were going to be rejected? - View all 2 replies
-
-
Iamstockgeniusjustaskme: $ARNA Thanks I think being in Mensa helped but also I like to thank my parents for their contribution in helping me get to this level.
-
- View all 2 replies
-
-
-
- View all 4 replies
-
-
-
Day Trader001
Good money to be made this week on the $ARNA bounce once again! This is better than an atm machine. - View all 2 replies
-
-
Day Trader001: "No News" as usual! This is a normal dip. Check out Recognia's chart info on Fidelity! Wow, Great move on BBRY!! good thing ya bailed!
-
- View all 1 replies
-
RSI Raistlin: closed $ARNA calls for .78...yea left some money on the table but in and out im happy with the profit
-
- View all 1 replies
-
Day Trader001: $8.00 has been a good bounce mark, but VVUS reports Monday that could affect the sector.
-
- View all 5 replies
-
Crazysight: Well u can't pick them all. Tthought it would probably keep falling the rest of the week, but the areniacs seem 2 b back with a vengeance. -
Crazysight: What a stock this ARNA is though. Never a dull moment with it!